Anticoagulation Not Routinely Needed After TAVR: ADAPT-TAVR

The ADAPT-TAVR trial showed a numerical reduction in leaflet thrombosis with edoxaban versus dual antiplatelet therapy, but no reduction in cerebral events or neurocognitive function
Medscape Medical News